Solarvest BioEnergy's New Fixed Stock Option Plan Accepted by TSXV; Option Grants to Directors, Officers and Consultants
Solarvest BioEnergy's New Fixed Stock Option Plan Accepted by TSXV; Option Grants to Directors, Officers and Consultants
As a result of the foregoing issuances and previously announced grants, as at the date hereof, the aggregate number of options issued and outstanding under the 2022 Plan is 8,575,000 leaving available 2,492,000 options available for future grants.Vancouver, British Columbia--(Newsfile Corp. - March 3, 2023) - Solarvest BioEnergy Inc. (TSXV: SVS) ("Solarvest" or the "Company") is pleased to announce that, further to its news releases of September 22 and November 3, 2022, the TSX Venture Exchange (the "Exchange") has accepted for filing its new fixed stock option plan (the "2022 Plan"). The 2022 Plan reserves a total of 11,067,000 common shares for issuance pursuant to the grant of stock options. All outstanding options from the Company's previous stock option plan have been rolled into the 2022 Plan effective March 1, 2023 and will be governed by its terms. Although disinterested shareholder approval for the 2022 Plan was obtained at the annual meeting of shareholders held on October 25, 2022, due to certain revisions required by the Exchange, further disinterested shareholder approval is required to be obtained at the next meeting of shareholders.
加拿大不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2023年3月3日)-Solarvest BioEnergy Inc.(多倫多證券交易所股票代碼：SVS)(以下簡稱“Solarvest”或“公司”)欣然宣佈，繼2022年9月22日和11月3日發佈新聞稿後，多倫多證券交易所創業板(以下簡稱“交易所”)已接受提交其新的固定股票期權計劃(“2022計劃”)。2022年計劃保留了總計11,067,000股普通股，以根據股票期權的授予進行發行。公司之前的股票期權計劃中的所有未償還期權已被納入2022年計劃，從2023年3月1日起生效，並將受其條款的約束。雖然於2022年10月25日舉行的股東周年大會上，因聯交所要求作出若干修訂而獲得公正股東對2022年計劃的批准，但仍需在下次股東大會上取得進一步公正股東的批准。
The Company also wishes to announce that, effective March 1, 2023, it has issued an aggregate of 2,500,000 stock options to various directors and officers, each option entitling the holder to acquire one common share of the Company at a price of $0.10 per share. Of these options, 750,000 expire on March 1, 2026, and are not subject to vesting. The remaining 1,750,000 options, which expire on October 6, 2026, have been granted to Claes Ellegaard, CEO, as part of his compensation arrangements and include the 750,000 disclosed in the Company's news release of October 18, 2022. Of the options granted to Mr. Ellegaard, 750,000 vest immediately while the balance are subject to vesting and are releasable based on certain performance criteria contained in Mr. Ellegard's compensation package.
本公司還希望宣佈，自2023年3月1日起，它已向多名董事和高級管理人員發行了總計2500,000份股票期權，每一份期權賦予持有人以每股0.10美元的價格收購公司一股普通股的權利。在這些期權中，75萬份將於2026年3月1日到期，不受歸屬的限制。剩餘的1,750,000份期權將於2026年10月6日到期，作為其薪酬安排的一部分，已授予首席執行官Claes ElLegaard，其中包括公司在2022年10月18日的新聞稿中披露的750,000份期權。在授予ElLegaard先生的期權中，750 000歐元立即歸屬，其餘部分可歸屬，並可根據Ellegard先生薪酬方案中所載的某些業績標準予以解除。
The Company also wishes to announce that, effective March 1, 2023, it has granted an aggregate of 1,780,000 stock options with an exercise price of $0.10 to various business consultants. The expiry dates of these options vary as they run concurrently with the consultant contracts although no consultant options expire any later than March 1, 2026.
該公司還希望宣佈，自2023年3月1日起，它已向各種商業顧問授予了總計178萬份行使價格為0.10美元的股票期權。這些期權的到期日期各不相同，因為它們與顧問合同同時生效，儘管沒有任何顧問期權在2026年3月1日之前到期。
As a result of the foregoing issuances and previously announced grants, as at the date hereof, the aggregate number of options issued and outstanding under the 2022 Plan is 8,575,000 leaving available 2,492,000 options available for future grants.
由於上述發行和先前宣佈的贈款，截至本報告日期，根據2022年計劃已發行和未償還的期權總數為8,575,000份，剩餘2,492,000份期權可用於未來的贈款。
About Solarvest
關於Solarvest
Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins.
Solarvest BioEnergy Inc.是一家藻類生物製品公司，其生產平臺為其提供了一個極其靈活的系統，能夠生產從歐米茄3脂肪酸到人類治療性蛋白質的各種產品。
For further information contact:
如需進一步資訊，請聯繫：
Claes Ellegaard
Phone: 1.514.898.3488
Email: invest@solarvest.ca
克萊斯·埃爾萊加德
電話：1.514.898.3488
電子郵件：Invest@solarvest.ca
Forward-Looking Statement
前瞻性陳述
This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.
本新聞稿包含前瞻性陳述，這些陳述與未來事件或未來業績有關，反映了管理層目前的預期和假設。這些前瞻性陳述反映了管理層目前的信念，是基於公司所做的假設和目前可獲得的資訊。請投資者注意，這些前瞻性陳述既不是承諾，也不是保證，可能會受到風險和不確定因素的影響，這些風險和不確定因素可能會導致未來的結果與預期的大不相同。這些前瞻性陳述是自本新聞稿發佈之日起作出的，除非適用的證券法規另有要求，否則公司不承擔任何更新或修訂這些陳述以反映新事件或新情況的義務。
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。